HER3-DXd showed promising clinical activity in patients with metastatic breast cancer and active brain metastases, and could offer a novel therapeutic option in this setting.
[Articles] Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
The Lancet Oncology | | Rupert Bartsch, Maximilian Marhold, Javier Garde-Noguera, María Gion, Manuel Ruiz-Borrego, Richard Greil, María Valero, Antonio Llombart-Cussac, Juan José García-Mosquera, Miriam Arumi, Javier Cortés, Marta Campolier, José Antonio Guerrero, Felipe Slebe, Elena Martínez-García, Carlos Jiménez-Cortegana, Marta Vaz-Batista, Felicitas Oberndorfer, Julia Furtner, Thorsten Fuereder, Anna Sophie Berghoff, Matthias Preusser
Topics: breast-cancer, brain-cancer, clinical-trials, research